Quality of Life Program: National Cultural Awards culminates support to Saudi culture, intellectuals    KSrelief Supports Early Recovery and Livelihoods Sector as Part of Saudi Arabia's Grant to Support Yemen Humanitarian Response Plan 2020    KSrelief Continues Distributing Ramadan Food Baskets in Lebanon    King, Crown Prince condoles Turkmen president on death of his father    Presidency to increase capacity of Mataf Courtyard, allocating 4 paths for elderly    India Reports New High of 1,761 Daily COVID-19 Deaths    Russia reports 8,164 new COVID-19 cases, 379 deaths    Custodian of the Two Holy Mosques Directs Disbursement of SR 1.9 Billion of Ramadan Aid for Social Insurance Beneficiaries    China administered total of 195.02 mln COVID-19 vaccines as of April 19    Prince Khalid meets with UK PM's envoy to Gulf region    10 million people in UK receive second dose of COVID-19 vaccine    Video clip showing expats being assaulted is old: Riyadh Police    US immigration agencies ordered to end use of terms 'alien' and 'assimilation'    US warns against travel to 80% of all countries due to COVID-19 State Department 'strongly recommends' US citizens reconsider any travel aborad    Chairman of Libyan Presidential Council Meets with Algerian Foreign Minister    In Jeel Tamooh's third edition, BCG experts, 100 world-class Saudi students come together    UAE government adopts 'blockchain' technology in authentication services    KSrelief signs two joint agreements to serve needy people in Yemen    Jadwa Investment partners with MHRSD to develop non-profit sector    Oilfields Supply Center's $570m investment in SPARK    SRC Obtains Good Ratings From Moody's, Fitch    National Center for Privatization Hosts Chinese Investors Forum    Saudi Stock Exchange Main Index Ends Trading Higher at 10,097 Points    Saudi Al-Hilal Defeats UAE Shabab Al-Ahli witn AFC Champions League    Saudi Al-Ahli, Qatari Al-Duhail Drew 1-1    Messi fires Barca to dominant Cup final win    Bayern moves closer to title but Flick says he's leaving    IRTI Report Showcases Sustainable Development Goals for IsDB Member States    Bayern move closer to title but Flick says he's leaving    The importance of legal specialization    Indian actor and environmentalist Vivek dies at age of 59    Alert over shortage of new drugs for 'world's most dangerous bacteria'    Helen McCrory, 'Harry Potter' and 'Peaky Blinders' star, dead at 52    New global compact aims to drive down diabetes deaths, boost insulin access    Welcome to beautiful Ramadan customs    Foundation stone laid for Jeddah Formula One circuit    Laying the Foundation Stone for Jeddah Formula One Circuit    King Salman Center for Disability Research Launches 2nd Edition of its Story Collection (Awareness)    Riyadh Light Witnesses Conclusion of External Artworks    Riyadh Light Turned the Capital into Lights' Aura    Colored Triangles Decorate Conference Building, at King Abdullah Financial Center    Vaccination does not invalidate fasting, says UAE Fatwa Council    It is high time to correct wrong concepts about women's status    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Court facilitates young woman's marriage after stripping father's guardianship    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Russian vaccine safe, induces antibody response in small human trials: Report
Published in The Saudi Gazette on 04 - 09 - 2020

According to an article published on Friday in The Lancet journal, Sputnik V, the world's first registered coronavirus vaccine, approved by Russia last month, has been shown to elicit antibody response with no serious adverse events in small human trials.
The publication of the article carrying preliminary results of the Phase I-II clinical trials of the vaccine was announced by the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and the Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation.
The scientific publication in The Lancet proves the high safety and efficacy of the Russian vaccine and also provides detailed data on the results of the clinical trials.
The article contains both the key qualitative and quantitative characteristics of the Sputnik V vaccine, favorably distinguishing it from other vaccines that are only just undergoing clinical trials in various countries and have no data on carcinogenicity or the effects on fertility.
Results from early-phase non-randomized vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.
Secondary outcomes from the trial suggest the vaccines also produce a T cell response within 28 days, the researchers said.
The findings are based on two small phase trials lasting 42 days — one studying a frozen formulation of the vaccine, and another involving a lyophilized (freeze-dried) formulation of the vaccine, they said.
The frozen formulation is envisaged for large-scale use in existing global supply chains for vaccines, while the freeze-dried formulation was developed for hard-to-reach regions as it is more stable and can be stored at 2-8 degrees Celsius, the researchers said.
The two-part vaccine includes recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S), which have been modified to express the SARS-CoV-2 spike protein.
The adenoviruses, which usually cause the common cold, are also weakened so that they cannot replicate in human cells and cannot cause disease, according to the researchers.
These vaccines aim to stimulate both arms of the immune system — antibody and T cell responses — so they attack the virus when it is circulating in the body, and also attack cells infected by SARS-CoV-2.
"When adenovirus vaccines enter people's cells, they deliver the SARS-CoV-2 spike protein genetic code, which causes cells to produce the spike protein," said study lead author Denis Logunov, from Gamaleya National Research Center.
"This helps teach the immune system to recognize and attack the SARS-CoV-2 virus. To form a powerful immune response against SARS-CoV-2, it is important that a booster vaccination is provided," Logunov said.
However, Logunov said, booster vaccinations that use the same adenovirus vector might not produce an effective response.
He said this is because the immune system may recognize and attack the vector, adding this would block the vaccine from entering people's cells and teaching the body to recognize and attack SARS-CoV-2.
"For our vaccine, we use two different adenovirus vectors in a bid to avoid the immune system becoming immune to the vector," Logunov added.
The trials took place in two hospitals in Russia, and were open-label and non-randomized, meaning that participants knew that they were receiving the vaccine and were not assigned by chance to different treatment groups.
The trials involved healthy adults aged 18-60 years, who self-isolated as soon as they were registered, and remained in hospital for the first 28 days of the trial from when they were first vaccinated.
In phase 1 of each trial, participants received one component of the two-part vaccine — four groups of nine participants were given the frozen or freeze-dried rAd26-S or rAd5-S component.
In phase 2, which began no earlier than five days after the phase 1 trial began, participants received the full two-part vaccine — they received a prime vaccination with the rAd26-S component on day 0, followed by a booster vaccination with rAd5-S component on day 21.
Both vaccine formulations were safe over the 42-day study period and well-tolerated, according to the study.
The most common adverse events were pain at the injection site, hyperthermia, headache, asthenia (weakness or lack of energy), and muscle and joint pain.
The authors note that these adverse effects are also seen with other vaccines, particularly those based on recombinant viral vectors. — Agencies


Clic here to read the story from its source.